APR-246 (eprenetapopt) + Acalabrutinib in CLL + APR-246 (eprenetapopt) 4.5 g/d + Venetoclax + Rituximab in CLL + APR-246 (eprenetapopt) 4.5 g/d + (Acalabrutinib, OR, (Venetoclax +Rituximab)), in CLL and/or MCL and/or RT + APR-246 (eprenetapopt) 4.5 g/d + Venetoclax + Rituximab in RT
Phase 1/2TerminatedDevelopment Stage
Non Hodgkin Lymphoma
Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma
Mar 2, 2021 → Aug 24, 2021
About APR-246 (eprenetapopt) + Acalabrutinib in CLL + APR-246 (eprenetapopt) 4.5 g/d + Venetoclax + Rituximab in CLL + APR-246 (eprenetapopt) 4.5 g/d + (Acalabrutinib, OR, (Venetoclax +Rituximab)), in CLL and/or MCL and/or RT + APR-246 (eprenetapopt) 4.5 g/d + Venetoclax + Rituximab in RT
APR-246 (eprenetapopt) + Acalabrutinib in CLL + APR-246 (eprenetapopt) 4.5 g/d + Venetoclax + Rituximab in CLL + APR-246 (eprenetapopt) 4.5 g/d + (Acalabrutinib, OR, (Venetoclax +Rituximab)), in CLL and/or MCL and/or RT + APR-246 (eprenetapopt) 4.5 g/d + Venetoclax + Rituximab in RT is a phase 1/2 stage product being developed by Aprea Therapeutics for Non Hodgkin Lymphoma. The current trial status is terminated. This product is registered under clinical trial identifier NCT04419389. Target conditions include Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma.
Hype Score Breakdown
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04419389 | Phase 1/2 | Terminated |
Competing Products
20 competing products in Non Hodgkin Lymphoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| AFM13 | Affimed | Phase 2 | 44 |
| VIP152 + BTKi | Vincerx Pharma | Phase 1 | 25 |
| PLX3397 | Daiichi Sankyo | Phase 2 | 52 |
| YM155 + Rituximab | Astellas Pharma | Phase 2 | 52 |
| Tazemetostat | Eisai | Phase 2 | 52 |
| ONTAK | Eisai | Phase 2 | 52 |
| Tazemetostat | Eisai | Phase 1 | 33 |
| ME-401 | Kyowa Kirin | Phase 1 | 33 |
| ME-401 | Kyowa Kirin | Phase 2 | 52 |
| Tirabrutinib | Ono Pharmaceutical | Phase 1 | 33 |
| ONO-7018 | Ono Pharmaceutical | Phase 1 | 33 |
| Nivolumab + Brentuximab vedotin | Ono Pharmaceutical | Phase 3 | 77 |
| ONO-7018 + ONO-7018 | Ono Pharmaceutical | Phase 1 | 33 |
| R-mabHDI and ABVD + ABVD | Eli Lilly | Phase 3 | 77 |
| Prednisone + Vinblastine + Doxorubicin (Adriamycin) + Gemcitabine | Eli Lilly | Phase 1/2 | 41 |
| gemcitabine | Eli Lilly | Phase 2 | 52 |
| gemcitabine + cisplatin + dexamethasone | Eli Lilly | Phase 2 | 52 |
| LY4152199 - IV | Eli Lilly | Phase 1 | 33 |
| R-mabHD + ABVD | Eli Lilly | Phase 2 | 52 |
| enzastaurin + placebo | Eli Lilly | Phase 3 | 77 |